Associations of Vitamin D Deficiency and Vitamin D Receptor Polymorphisms With the Risk of Primary Open-angle Glaucoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02539745

Enrollment

200

Registered

2015-09-03

Start date

2013-07-31

Completion date

2015-03-31

Last updated

2016-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Open- Angle Glaucoma, Vitamin D Deficiency

Keywords

vitamin D, primary open- angle glaucoma

Brief summary

This study investigated whether vitamin D receptor gene polymorphism is altered in primary open-angle glaucoma subjects carrying the risk allele and vitamin D deficiency is an important factor in the development of glaucoma. Primary open-angle glaucoma patients and age-matched people in the Han population were enrolled. Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay. Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.

Interventions

OTHERVitamin D receptor polymorphic analysis

Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.

OTHERSerum levels of 1a, 25-Dihydroxyvitamin D3

Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

55 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* intraocular pressure greater than 22 mmHg with two or more medications * wide anterior chamber angle * glaucomatous optic neuropathy (Glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect) * visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry

Exclusion criteria

* the presence of any secondary glaucoma including exfoliation syndrome or a history of ocular trauma * high myopia * macular degeneration * other ocular diseases * a known history of systemic diseases and administration of vitamin D3 or other analog

Design outcomes

Primary

Measure	Time frame
Serum levels of 1a, 25-Dihydroxyvitamin D3	1 day visit

Secondary

Measure	Time frame
gene polymorphisms of vitamin D receptor	1 day visit

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026